Perampanel, a novel neuroprotector and antiviral agent in COVID-19?

2020 · doi:10.32388/0ugee9
preprint OA: closed CC-BY-4.0
🔓 Open OA copy Full text JSON View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-15 ⓘ

Perampanel, an epilepsy drug targeting AMPA receptors, is proposed to have neuroprotective and antiviral effects in COVID-19 by modulating glutamate, similar to memantine's action on NMDA receptors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-15 · read from full text ⓘ

This paper is an overview-style article discussing perampanel as a potential neuroprotector and antiviral agent in the context of COVID-19. It characterizes perampanel’s proposed roles rather than presenting new experimental results within the provided text. A clear limitation is that the provided content does not include the study methods, population, or any specific efficacy or safety findings, making the evidentiary basis unspecified here. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract A new human coronaviruses (SARS-CoV-2) are the cause of currently severe acute respiratory syndrome (SARS), as occurred in the previous epidemic caused by SARS-CoV-1. Perampanel is a drug currently used in epilepsy, with an innovative mechanism of action, through receptors [2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) that modulates the flow of glutamate. It has been reported the utility of another drugs used in neurodegenerative disorders such a memantine. It works through the N-methyl-D-aspartate receptor (NMDA) and regulates the transporting of glutamate. Both are receptor antagonists. Memantine has seen to reduce the symptoms and replication viral in animal models infected with HCoV. We propose that perampanel works in a similar way and may have therapeutic and neuroprotective effects in COVID-19 infection. New studies on it should be started.
Full text 621 characters · extracted from oa-doi-fallback · click to expand
There is a newer version available for this {{ publicationType }}. View latest version {{ publication.field_name }} {{ publication.subfield_name }} Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Check the {{ publicationType | capitalize }} Source for copyright and license information. Listen on

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0